Erectile dysfunction as the first signal of cardiovascular diseases and the importance of diagnostics

Czech version

Authors: T. Šrámková
Authors‘ workplace: Sexuologické oddělení FN Brno ; Urologická klinika a Sexuologický ústav 1. LF UK a VFN Praha
Published in: Urol List 2014; 12(1): 11-14

Overview

Erectile dysfunction is associated with the endothelial dysfunction and/or with the atherosclerosis and silent myocardial ischaemia. Endothelial dysfunction is the first stage of cardiovascular diseases. Men with erectile dysfunction must be examined in connection with cardiovascular disease including coronary artery disease. Diagnosis and therapy of ED in men with cardiovascular diseases is based on the principles of the Princeton Consensus. Oral form of ED treatment using PDE5 inhibitors and intracavernosal injections of prostaglandin E1 in men with cardiovascular diseases is safe, effective and is well-tolerated.

Key words:
endothelial dysfunction, erectile dysfunction, cardiovascular disease, coronary artery disease, Princeton Consensus, therapy

Sources

1. Costa C, Virag R. The endothelial‑ erectile dysfunction connection: an essential update. J Sex Med 2009; 6(9): 2390– 2404. doi: 10.1111/ j.1743- 6109.2009.01356.x.

2. Meluzín J. Erektilní dysfunkce a srdce. In: Pacík D. (ed). Erektilní dysfunkce pod lupou. Plzeň: Adéla 2005: 9– 16.

3. Jackson G. Prediction of coronary artery disease by erectile function status: evidence‑based data. Sex Med Rev 2013; 1: 104– 107. doi: 10.1002/ smrj.12.

4. Kloner R, Padma‑ Nathan H. Erectile dysfunction in patients with coronary artery disease. Int J Impot Res 2005; 17(3): 209– 215.

5. Jackson G, Boon N, Eardley I et al. Erectile dysfunction and coronary artery disease prediction: evidence‑based guidance and consensus. Int J Clin Pract 2010; 64(7): 848– 857. doi: 10.1111/ j.1742- 1241.2010.02410.x.

6. Kirby M, Jackson G, Betteridge J et al. Is erectile function a marker for cardiovascular disease? Int J Clin Prakt 2001; 55(9): 614– 618.

7. Ewane KA, Lin HC, Wang R. Should patients with erectile dysfunction be evaluated for cardiovascular disease? Asian J Androl 2012; 14(1): 138– 144. doi: 10.1038/ aja.2011.137.

8. Shin D, Pregenzer G Jr, Gardin JM. Erectile dysfunction: a disease marker for cardiovascular disease. Cardiol Rev 2011; 19(1): 5– 11. doi: 10.1097/ CRD.0b013e3181fb7eb8.

9. Montorsi P, Ravagnani PM, Galli S et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol 2005; 96(12B): 19M‑ 23M.

10. Greenstein A, Chen J, Miller H et al. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997; 9(3): 123– 126.

11. De Busk R, Drory Y, Goldstein I et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000; 86(2): 175– 181.

12. Jackson G, Rosen RC, Kloner RA et al. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006; 3(1): 28– 36.

13. Nehra A, Jackson G, Miner M et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87(8): 766– 778. doi: 10.1016/ j.mayocp.2012.06.015.

14. Kaiser DR, Billups K, Mason C et al. Impaired brachial artery endothelium‑ dependent and - independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43(2): 179– 184.

15. Tamler R, Bar‑ Chama N. Assessment of endothelial function in the patient with erectile dysfunction: an opportunity for the urologist. Int J Impot Res 2008; 20(4): 370– 377. doi: 10.1038/ ijir.2008.13.

16. Muller JE, Mittleman MA, Maclure M et al. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA 1996; 275: 1405– 1409.

17. Wespes E, Eardley I, Giuliano F et al. Male sexual dysfunction: Erectile dysfunction and premature ejaculation. Available from: Guidelines EAU 2013. Available from: http:/ / www.uroweb.org/ guidelines/ online‑ guidelines/ ?no_cache=1.

18. Šrámková T. Poruchy sexuality u somaticky nemocných a jejich léčba. Praha: Grada Publishing 2013.

19. Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999; 83(5A): 29C‑ 34C.

20. Jackson G, Kloner RA, Costigan TM et al. Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sex Med 2004; 1(2): 161– 167.

21. Zusman RM. Cardiovascular data on sildenafil citrate: introduction. Am J Cardiol 1999; 83(5A): 1C‑ 2C.

22. Aversa A, Vitalec C, Volterrani M et al. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med 2008; 25(1): 37– 44. doi: 10.1111/ j.1464- 5491.2007.02298.x.

23. Foresta C, Ferlin A, De Toni L et al. Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res 2006; 18(5): 484– 488.

24. Býma S, Hradec J. Prevence kardiovaskulárních onemocnění. Doporučený diagnostický a léčebný postup po všeobecné lékaře. Praha: Centrum doporučených postupů pro praktické lékaře 2004.

25. Gupta BP, Murad MH, Clifton MM et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction. Arch Intern Med 2011; 171(20): 1797– 1803. doi: 10.1001/ archinternmed.2011.440.